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Abstract  More  than  90%  of  the  population  is  infected  by  Epstein-Barr  virus  (EBV),  which  has
sophisticatedly  evolved  to  survive  silently  in  B  cells  for  the  life  of  infected  individuals.  However,
if the  virus-host  balance  is  disturbed,  latent  EBV  infection  could  be  associated  with  several  lym-
phomas. The  age  at  primary  infection  varies  substantially  worldwide,  and  exposure  to  EBV  is
likely to  be  due  to  socioeconomic  factors.  In  Argentina,  EBV  infection  is  mostly  subclinical  and
90% of  patients  are  seropositive  by  the  age  of  3  years;  therefore,  its  epidemiological  charac-
teristics  resemble  those  of  an  underdeveloped  or  developing  population.  EBV-positive  Hodgkin
lymphoma  (HL)  in  young  adults  from  developed  populations  has  been  attributed  to  delayed
primary EBV  infection  as  suggested  by  the  association  with  recent  mononucleosis  development.
EBV-associated  Burkitt  lymphoma  and  Hodgkin  lymphoma  in  children  from  Argentina  display  fre-
quencies similar  to  those  observed  in  developed  countries,  whereas  EBV  presence  in  pediatric
diffuse large  B-cell  lymphoma  is  slightly  increased  compared  to  those  populations.  However,
EBV presence  is  statistically  associated  particularly  with  patients  <  10  years  of  age  in  all  three
entities. Therefore,  a  relationship  between  low  age  of  EBV  seroconversion  and  B-cell  lymphoma
development  risk  could  be  suggested  in  children  from  Argentina.
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pstein--Barr  virus  (EBV)  is  a  ubiquitous  double-stranded  DNA
irus  that  belongs  to  the  Herpesviridae  family  and  Gamma-
erpesvirinae  subfamily.  EBV  is  characterized  by  a  tropism
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or  B-lymphocytes  displaying  latent  infection  in  the  host  and
he  capacity  for  transforming  B-lymphocytes.  More  than  90%
f  the  population  worldwide  carries  the  virus,1 which  has
ophisticatedly  evolved  to  survive  in  B  cells  for  the  life  of
nfected  individuals.  The  result  is  a  finely  balanced  rela-
ionship  that  allows  the  virus  to  be  acquired  silently  early
n  life  and  carried  thereafter  as  a  lifelong  asymptomatic
nfection  in  the  B  lymphoid  system.  However,  the  virus-
ost  balance  can  be  disturbed  in  various  ways,  and  one
f  a  range  of  virus-associated  diseases  may  then  ensue.2
atent  EBV  infection  is  linked  to  many  human  malignancies.
n  immunocompetent  persons,  EBV  is  associated  with  ∼20%
f  Burkitt  lymphoma  (BL)  in  the  developed  world,  almost
ll  African  BL,  50%  of  Hodgkin  lymphoma  (HL),  10%  gas-
ric  carcinomas  (GCs),  almost  all  endemic  nasopharyngeal
arcinoma  (NPC),  certain  fractions  of  diffuse  large  B-cell
ymphoma  and  T-cell  lymphoma.  In  the  absence  of  nor-
al  T-cell  immune  responses,  EBV-infected  B-lymphocyte
roliferations  can  cause  lymphoproliferative  disease  (LPD),
imilar  to  post-transplant  LPD.  The  persistence  of  EBV
enomes  in  cells  of  these  malignancies,  even  in  subjects  with
therwise  normal  immune  response,  is  consistent  with  the
otion  that  EBV  genomes  are  important  for  malignant  cell
rowth.3
The  age  at  primary  infection  varies  substantially  world-
ide,  and  exposure  to  EBV  is  likely  to  be  due  to
ocioeconomic  factors.  Young  children  most  likely  acquire
rimary  EBV  infection  due  to  close  contact  that  involves
xchange  of  oral  secretions  via  shared  items  such  as  toys,
ottles,  and  utensils.  Before  the  age  of  10  years,  pri-
ary  infection  is  usually  asymptomatic.  In  adolescents  and
oung  adults,  however,  primary  EBV  infection  frequently
resents  as  infectious  mononucleosis  (IM).  Seroprevalence
f  EBV  varies  widely  by  geographic  location.  Data  indicate
hat  primary  EBV  infection  occurs  at  a  younger  age  among
ersons  from  lower  vs.  higher  socioeconomic  backgrounds,
hich  has  been  attributed  to  crowded  living  conditions.4
 delay  in  acquiring  a  primary  EBV  infection  at  an  older
ge  in  childhood  or  adolescence,  which  usually  occurs  in
ore  developed  countries,  can  manifest  itself  as  infec-
ious  mononucleosis,  occurring  in  ∼25--75%  of  EBV-infected
ersons.5 The  severity  of  primary  EBV  infection  in  adults
ncreases  with  age,  and  patients  >  40  years  of  age  are  espe-
ially  prone  to  serious  illness.  EBV  infections  in  children
 10  years  are  often  overlooked,  either  because  they  are
ntirely  asymptomatic  or  because  they  do  not  present  with
 typical  IM  syndrome.4
There  is  a  hypothesis  that  proposes  that  the  clinical
resentation  variability  related  to  the  age  of  EBV  pri-
ary  infection  is  linked  to  the  different  magnitude  of  the
iral  dose  received  by  a  child  or  a  young  adult  through
alivary  contact.6 Another  possibility  is  that  IM  in  adoles-
ents  may  reflect  the  global  CD8+  T-cell  lymphocytosis,
ith  a  great  proportion  of  activated  EBV-specific  CD8+  T-
ells.7 In  contrast,  it  was  recently  described  in  children
rom  Africa  that  asymptomatic  EBV  infection  elicits  a  virus-
pecific  CD8+  T-cell  response  that  can  control  the  infection,
ithout  CD8+  T-cells  over-expansion.8 Moreover,  it  was  sug-Please  cite  this  article  in  press  as:  Chabay  P,  Preciado  MV.  Epi
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ested  that  preexisting  NK  cell  populations  in  children  may
rovide  an  explanation  for  why  IM  occurs  more  frequently
n  adolescents  and  adults  than  in  children.9 In  Argentina,






P.  Chabay,  M.V.  Preciado
eropositive  by  the  age  of  3  years;  therefore,  its  epidemio-
ogical  characteristics  resemble  those  of  an  underdeveloped
r  developing  population.10
. EBV infection in relation to lymphoma
evelopment
s  previously  mentioned,  EBV  is  among  the  infectious
gents  whose  clinical  manifestations  vary  according  to  age
t  primary  infection.  Moreover,  its  epidemiological  behav-
or  is  similar  to  that  of  HL.  The  relatively  few  cases  of
BV-positive  HL  in  younger  adults  may  be  attributed  to
elayed  primary  EBV  infection  as  suggested  by  the  asso-
iation  with  mononucleosis.11 In  fact,  IM  was  associated
ith  an  increased  risk  of  EBV-positive  HL,  along  with  the
articularly  pronounced  risk  in  younger  adults.  Further-
ore,  IM-associated  lymphomas  occurred  with  a  median  of
.9  years  after  infection  in  patients  from  a  developed  popu-
ation.  Although  the  idea  that  EBV  is  merely  an  etiologically
nnocent  passenger  in  the  neoplastic  HL  cells  cannot  eas-
ly  be  dismissed,  it  remains  more  likely  that  the  observed
ssociation  indeed  reflects  causality,12 at  least  in  cases  with
ecent  IM  development.  In  contrast,  no  associations  between
BV  serology  status,  elevated  antibody  titers  against  EBNA-
,  EBNA-2,  VCA,  or  EA,  and  risk  of  NHL  overall  was
emonstrated  in  immunocompetent  individuals,  with  the
ossible  exception  of  chronic  lymphocytic  leukemia  (CLL).
herefore,  it  was  proposed  that  the  biological  mechanism
or  the  causal  role  of  EBV  in  the  pathogenesis  of  NHL  would
redominantly  involve  immune  system  deregulation.13
The  temporal  risk  variation  in  HL  risk  after  IM  suggests
hat  the  predilection  for  the  younger  adult  age  group  may
imply  result  from  the  combination  of  age  and  time  since
M  rather  than  from  other  mechanisms  particular  to  HL  in
ounger  adults.14 It  is  therefore  tempting  to  speculate  that  a
imilar  association  may  exist  between  primary  EBV  infection
nd  HL  risk  at  any  age,  e.g.,  in  childhood.12 EBV  epidemiol-
gy  in  Argentina  reflects  a  typical  pattern  of  a  developing
ountry  with  primary  infection  in  early  childhood  and  the
pidemiology  of  EBV-related  lymphomas  differs  from  that
bserved  in  developing  countries.  Therefore,  EBV  infection
n  our  pediatric  patients  shows  a  complex  epidemiological
attern,  very  attractive  to  investigate.
. EBV in pediatric Hodgkin lymphoma
n  the  United  States  and  most  European  countries,  HL  shows
n  annual  incidence  of  4.5-6.0  per  million  and  its  incidence
ncreases  with  age  and  peaks  between  15  and  30  years.
n  contrast,  in  developing  countries,  it  shows  a  high  inci-
ence  in  children  exceeding  7  per  million  per  annum  and
0%  of  cases  occur  in  children  <  10  years  of  age.15 EBV  pres-
nce  in  HL  varies  with  geographic  location,  age,  sex,  clinical
tage,  and  histologic  type.  EBV  is  detected  in  Hodgkin
eed-Sternberg  (HRS)  cells  in  ∼40%  of  classical  Hodgkin’s
ymphoma  in  the  Western  world,  mostly  in  cases  of  mixed
ellularity  (MC)  and  lymphocyte-depleted  subtypes,  and  lessdemiology  of  Epstein-Barr  virus-associated  pediatric  lym-
/dx.doi.org/10.1016/j.bmhimx.2015.12.002
requently  in  nodular  sclerosis  and  lymphocyte-rich  classical
ubtypes.  EBV  is  rarely  found  in  nodular  lymphocyte  predom-
nant  HL  (NLPHL).16 Developing  countries  have  an  increased
























































tumors;  however,  it  is  clear  that  germinal  center  involve-
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the  existence  of  underlying  immunosuppression.17 In  addi-
tion,  in  developed  populations  EBV-positive  HL  also  affects
more  Asians  and  Hispanics  than  whites  or  blacks  and  in  the
UK  is  more  common  in  South  Asian  children  compared  with
non-South  Asian  children.15
Childhood  HL  is  defined  as  affecting  those  patients
≤16  years  of  age.  It  represents  ∼10%  of  all  diagnosed  HL
and  typically  shows  a  significant  prevalence  of  male  gender
and  MC  (30-35%)  in  comparison  with  HL  in  adolescent/young
adults  or  adults.  Like  its  adult  counterpart,  ∼40-50%  of  HL
cases  are  associated  with  EBV  in  developed  countries.18 HL
is  more  likely  to  be  EBV-associated  to  boys  <  10  years  of  age
than  to  young  adults.  This  led  to  the  suggestion  that  HL  con-
sists  of  three  disease  entities:  pediatric  HL  (EBV-positive,
mixed  cellularity  type),  HL  of  young  adults  (EBV-negative,
nodular  sclerosis  type),  and  HL  of  older  adults  (EBV-positive,
mixed  cellularity  type).15
In  Argentina,  our  group  previously  reported  an  epidemio-
logical  pattern  II  together  with  an  EBV  association  of  31%  for
adult  HL,  which  rose  up  to  54%  in  pediatric  patients.19--21 In
pediatric  Hodgkin’s  lymphoma  in  Central  and  South  Amer-
ica,  several  groups  demonstrated  an  EBV-association  that
could  be  up  to  90%.16 Therefore,  EBV  presence  in  child-
hood  HL  from  our  series  resembles  the  scenario  observed
in  developed  countries.  In  spite  of  this,  EBV  was  statistically
associated  with  MC  subtype  and  males  (p  <  0.05,  2 test),
typical  of  an  underdeveloped  or  developing  population.  In
addition,  when  only  children  <  10  years  of  age  were  ana-
lyzed,  they  displayed  distinctive  characteristics.  EBV  was
statistically  distributed  in  74%  of  patients  <  10  years  of
age  vs.  34%  observed  in  patients  11-16  years  (p  <  0.0001,
2 test).  Furthermore,  EBV+  cases  had  a  median  age  of
8  years  vs.  a  median  of  12  years  observed  in  EBV-  cases
(p  =  0.006,  Mann-Whitney  test)  (authors’  unpublished  data).
These  paradoxical  epidemiological  characteristics  make  our
population  a  quite  interesting  group  for  analysis.  In  con-
trast,  in  southeast  Brazil,  where  both  EBV  primary  infection
and  EBV-associated  pediatric  HL  reveal  the  same  pattern
as  in  Argentina,  EBV+  HL  was  not  significantly  distributed
in  patients  <  10  years  of  age  or  MC  subtype.22,23 However,
childhood  HL  from  northeast  Brazil  display  87%  of  EBV+  cases
together  with  a  prevalence  of  MC  subtype,24 as  in  underde-
veloped  populations.  In  line  with  this,  Mexico  and  Peru  also
showed  a  high  frequency  of  EBV-associated  HL,  70%  and  94%,
respectively.25,26
EBV-associated  tumors  display  three  classical  patterns
with  differential  expression  of  latency  proteins,  in  part
as  a  consequence  of  host  immune  response  to  EBV  anti-
gens.  Latency  III  expresses  EBNA1,  -2,  -3A,  -3B,  -3C,  -LP
together  with  LMP1  and  -2  and  the  non-coding  RNAs  (EBERs,
microRNAs,  and  BARTs),  typically  associated  with  post-
transplant  lymphoproliferative  disorders.  All  other  latency
types  involve  increasing  degrees  of  viral  gene  silencing.
In  latency  I,  observed  in  BL,  only  EBNA1  and  the  non-
coding  RNAs  are  expressed,  whereas  EBNA1,  LMP1  and  -2
and  the  non-coding  RNAs  are  expressed  in  the  latency  II
program,  related  to  HL.27 It  was  proposed  that  LMP1  res-
cue  pro-apoptotic  germinal  center  B-cells  with  crippling
mutations  in  the  heavy  chain  immunoglobulin  locus  fromPlease  cite  this  article  in  press  as:  Chabay  P,  Preciado  MV.  Epi
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apoptosis,28 whereas  LMP2A  may  act  as  an  indispensable
BCR-mimic  in  BCR-positive  and  BCR-negative  germinal  cen-
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hese  cells  from  apoptosis  and  in  the  HL  transformation
rocess  as  well.  On  the  other  hand,  Thorley-Lawson  et  al.
uggested  a  modest  signaling  role  for  LMP1  and  LMP2A  in
C  B-cells,  based  on  the  presence  of  high  affinity  antibodies
n  LMP1+  and  2A+  germinal  center  B-cells.30 In  Argentina,
e  found  latency  II  pattern  in  our  HL  series,  defined  by
MP1  expression  in  cytoplasm  membrane  of  HRS  cells.  Given
hat  HRS  cells  derive  from  crippled,  pre-apoptotic  germi-
al  center  B  cells,16 LMP1  expression  in  our  cases  could  be
esponsible  for  rescuing  those  cells  from  apoptotic  stimuli.
n  a  preliminary  study  of  LMP1  expression  in  tonsils  from
ediatric  EBV+  patients,  we  found  that  LMP1+  cells  were
revalent  outside  the  germinal  centers  (authors’  unpub-
ished  data).  This  fact  could  imply  that  LMP1  presence  in
nly  a  small  number  of  cases  might  prevent  apoptosis  and
ead  to  first  steps  in  malignant  transformation  towards  HRS
ells.
The  risk  of  HL  after  IM  suggests  that  the  predilection  for
he  younger  adult  age  group  may  simply  result  from  the  com-
ination  of  age  and  time  since  IM.  Therefore,  given  the  fact
hat  in  Argentina  primary  infection  occurs  at  early  age  and
s  mostly  subclinical,  and  HL  prevail  in  patients  < 10  years
ld,  a  similar  association  may  exist  between  primary  EBV
nfection  and  HL  risk  in  childhood.
.  EBV in pediatric Burkitt lymphoma
urkitt  lymphoma  (BL)  can  be  classified  into  three  forms,
hich  differ  in  geographic  distribution  and  Epstein--Barr
irus  (EBV)  association:  endemic  (eBL),  sporadic  (sBL)  and
IV-associated  BL.31 The  high-incidence  ‘‘endemic’’  form
ypically  presents  as  a  jaw  or  abdominal  tumor  in  children
n  areas  of  equatorial  Africa  and  Papua  New  Guinea  where
alaria  is  holoendemic  and  is  almost  100%  EBV+.  Elsewhere,
L  occurs  in  ‘‘sporadic’’  form,  again  mainly  in  children,  at
ntermediate  to  low  incidence  and  with  different  degrees  of
BV  association  depending  upon  the  area.  Western  countries
how  the  lowest  incidence  rates  and  the  weakest  virus  asso-
iation,  with  only  15%  to  20%  tumors  being  EBV+.  Remark-
bly,  a  third,  adult  form  of  the  tumor,  AIDS-BL,  proved  to  be
ery  common  among  HIV-infected  individuals,  often  appear-
ng  as  one  of  the  first  symptoms  of  AIDS;  30%  to  40%  of
hese  tumors  carry  EBV.32 The  hallmark  of  all  BL  tumors
s  the  translocation  between  the  MYC  gene  and  one  of  the
mmunoglobulin  (Ig)  heavy  or  light  chain  loci.31 Burkitt  lym-
homa  cells  phenotypically  resemble  centroblasts.  More-
ver,  many  Burkitt  lymphoma  cells  and  also  some  Burkitt
ymphoma-derived  cell  lines  show  evidence  of  active  SHM,
 further  hallmark  of  germinal-center  B  cells.  The  structure
f  the  chromosome  breakpoints  derived  from  the  analysis  of
YC-Ig  translocations  strongly  indicates  that  the  transloca-
ions  occurred  either  as  a  mistake  of  class  switch  recombi-
ation  or  somatic  hypermutation,  both  processes  that  occur
n  germinal-center  B  cells.33 There  is  some  evidence  that  the
riginal  cell  may  derive  from  a  post-GC  or  memory  B  cell  re-
ntering  the  GC  and  may  differ  in  EBV-positive  and  -negativedemiology  of  Epstein-Barr  virus-associated  pediatric  lym-
/dx.doi.org/10.1016/j.bmhimx.2015.12.002
ent  is  critical  for  the  pathogenesis  of  this  disease  both  in
erms  of  MYC  translocation  events  and  the  contribution  of
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In  Argentina,  our  group  demonstrated  an  EBV  association
ith  pediatric  BL  in  37%  of  cases,  including  immunocom-
etent  and  immunocompromised  patients.  All  HIV+  patients
100%)  were  EBV+,  whereas  29%  of  the  immunocompetent
atients  displayed  EBV  presence  in  tumor  cells.  EBV  pres-
nce  in  Burkitt  lymphoma  biopsies  was  analyzed  according
o  age,  and  the  virus  was  statistically  distributed  in  patients
 5  years  old  (p  <  0.0001,  2 test).  Furthermore,  as  also
emonstrated  for  EBV-associated  HL,  the  median  age  of
BV-positive  patients  was  lower  (3  years  old)  than  that
bserved  for  EBV  negative  ones  (8  years  old)  (p  =  0.0027,
ann--Whitney  test).34 Remarkably,  a  sporadic  EBV  associ-
tion  with  Burkitt  lymphoma  (29%)  in  immunocompetent
atients  was  observed  in  our  series.  In  contrast,  variable
egionally  EBV  association  with  Burkitt’s  lymphoma  was
escribed  in  Brazil,  varying  from  29%  in  the  South  to  76%  in
he  North,  but  higher  in  pediatric  groups  from  all  regions.35
he  scenario  for  Burkitt  lymphoma  in  HIV-infected  patients
as  quite  different  from  that  described  previously  because
hese  series  showed  an  interesting  100%  EBV  association
ith  pediatric  Burkitt  lymphoma  patients  infected  with  HIV,
igher  than  the  typical  30-40%  reported  for  this  entity.32
Latency  I  pattern  seen  in  most  endemic  BL  tumors  is
haracterized  by  the  restricted  expression  of  a  single  latent
ntigen  EBNA1  transcribed  from  Qp  viral  promoter,  different
rom  the  latency  III  EBNA  transcripts,  which  are  driven  by
ither  of  two  promoters,  Cp  or  Wp.  However,  another  type
f  latency,  termed  Wp-restricted  latency,  characterized  by
xpression  of  EBNA1,  EBNA3A,  EBNA3B,  EBNA3C,  EBNA-LP
nd  BHRF1in  the  absence  of  EBNA2  and  the  LMPs,  was
lso  demonstrated  in  a  subset  of  endemic  BL  tumors  that
arry  EBV  genomes  deleted  for  the  EBNA2  gene.33 For  that
eason,  we  studied  viral  latency  profiles  by  LMP1  immuno-
istochemistry  and  RT-PCR.  Most  EBV+  cases  (80%)  displayed
he  typical  latency  I  profile  described  in  BL,  whereas  the
emaining  20%  showed  also  LMP1  immunohistochemical
xpression,  remarkably  those  cases  were  HIV-infected
atients.  This  pattern  did  not  match  either  with  latency  I
r  Wp-restricted  pattern  described  for  Burkitt  lymphoma  or
ith  latency  III  pattern  associated  with  EBV-positive  lym-
homas  in  immunosuppressed  patients.  In  addition,  LMP2A
atent  gene  as  well  as  BZLF1  and  BHRF1  lytic  genes  were  not
etected  by  RT-PCR,  whereas  EBNA1  transcripts  driven  from
p  promoters  were  demonstrated  in  the  absence  of  Wp/Cp
romoter  usage.34 Only  one  group  has  previously  reported
MP1  expression  without  LMP2A  by  RT-PCR  in  2  eBL  patients
rom  Africa.36 It  can  be  hypothesized  that  LMP1  expression
n  Burkitt  lymphoma  patients  infected  with  HIV  could  arise
rom  a  germinal  center  cell  that  failed  to  turn-off  selectively
MP1  expression  to  achieve  the  full  Burkitt’s  lymphoma
atency  I  phenotype,  promoted  by  HIV  presence.  Alterna-
ively,  the  presence  of  HIV-associated  immunosuppression
llows  the  unchecked  proliferation  of  EBV-infected  lym-
hocytes  expressing  latent  antigens  different  from  typical
atency  I.34
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orldwide,  diffuse  large  B-cell  lymphoma  (DLBCL)  repre-
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NHL),  accounting  for  30%  to  40%  of  all  newly  diagnosed
ases.  Two  distinct  subtypes  have  been  identified,  termed
erminal  center  cell  (GC)  and  post-germinal  center  (post-
C),  which  are  believed  to  represent  lymphomas  arising
rom  different  stages  of  lymphoid  differentiation.37 The
008  World  Health  Organization  (WHO)  classification  of
umors  of  hematopoietic  and  lymphoid  tissues  has  recog-
ized  a  new  provisional  entity  designated  as  EBV-positive
LBCL  of  the  elderly.  It  has  been  postulated  that  EBV-
ositive  DLBCL  of  the  elderly  might  be  caused  by  the
enescence  of  the  immune  system  as  a  part  of  the  nor-
al  aging  process,  based  largely  on  shared  features  with
mmunodeficiency-associated  lymphoproliferative  disorders
LPDs).38 The  age  cutoff  for  EBV-positive  DLBCL  was  set  as
 50  years.  However,  recent  reports  show  that  EBV-positive
LBCL  can  affect  younger  patients,39 including  our  study.40
urthermore,  in  some  previous  reports,  patients  <  50  years
ld  were  even  excluded  from  the  studies.39 Therefore,  it
s  not  evident  that  EBV-positive  DLBCL  in  young  adults  has
istinct  clinical  features  and  outcome  compared  to  their
lderly  counterpart.
DLBCL  is  rarely  diagnosed  in  children  <  4  years  of  age,
ut  the  proportion  of  patients  with  DLBCL  increases  through-
ut  childhood  toward  the  second  decade  of  life.41 The  role
f  EBV  in  pediatric  DLBCL  pathogenesis  remains  uncertain;
herefore,  we  assessed  EBV  association  as  well  as  viral  gene
xpression  in  the  DLBCL  pediatric  population  from  our  hos-
ital.  EBV  association  with  DLBCL  rose  up  to  40%,  using  20%
f  EBERs+  cells  as  cut-off  value;  nevertheless,  when  exclud-
ng  immunosuppressed  patients,  this  association  decreased
o  26%.42 There  are  only  few  studies  dealing  with  EBV  pres-
nce  in  DLBCL.  Our  overall  percentage  was  very  similar  to
hose  observed  in  previous  reports  restricted  to  African  chil-
ren,  which  analyzed  series  of  NHL  that  included  a  subset  of
LBCL  and  described  an  association  of  43-44%  between  EBV
nd  this  lymphoma  subtype,  even  though  the  immunolog-
cal  status  of  these  patients  was  not  clearly  specified.43,44
BV  presence  in  pediatric  DLBCL  patients  was  sorted  in
wo  age  groups:  less  than  10  years  (≤10  years)  and  11--16
ears  (>10  years).  The  number  of  EBV+  cases  was  signifi-
antly  higher  among  patients  ≤10  years  than  among  patients
 10  years  (p  <  0.018,  Fisher’s  exact  test).  Moreover,  median
ge  of  EBV-positive  patients  was  6  years  vs.  11  years
bserved  in  the  negative  patients  (p  =  0.005,  Mann  Whitney
est).  This  observation  together  with  the  high  association
n  childhood  HL  as  well  as  BL  confirms  that  EBV  could  be
n  important  cofactor  in  B-cell  lymphomagenesis  in  younger
hildren  in  Argentina.42
Previous  studies  suggested  that  EBV+  DLBCL  in  elderly
atients  generally  showed  a  viral  latency  type  II  or  III
attern,45,46 whereas  viral  latency  pattern  was  not  previ-
usly  described  in  pediatric  and  young  adults  patients.  In
ur  pediatric  DLBCL  series,  latency  pattern  III  was  the  most
requently  observed  together  with  lytic  gene  expression,
ollowed  by  latency  II  pattern.42 BZLF1  lytic  gene  expression
ould  mirror  a  percentage  of  cells  undergoing  lytic  phase,
s  previously  observed  for  BL.47 A  mixture  of  latency  II
r  III  and  a  lytic  EBV  gene  was  also  observed  in  our  adultdemiology  of  Epstein-Barr  virus-associated  pediatric  lym-
/dx.doi.org/10.1016/j.bmhimx.2015.12.002
ymphoma  series  from  Argentina,  in  both  patients  younger
nd  older  than  50  years.40 This  finding  suggests  that  the
ntity  EBV+  DLBCL  of  the  elderly  can  occur  in  pediatric










































































Table  1  Comparison  between  EBV  positive  and  negative  pediatric  lymphomas  between  developed  countries  and  Argentina.










4.5-6.0  6.94  Annual  inci-
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Uncertain  2.93  Annual  inci-
dence/million
Uncertain  Uncertain




































% of  EBV+  ≥10  y
group
Uncertain  34%  %  of  EBV+
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sBL = sporadic Burkitt lymphoma, HIVaBL = HIV-associated Burkitt lymphoma; IC DLBCL = immunocompetent diffuse large B-cell lymphoma and HIVaDLBC = HIV-associated diffuse large B-cell
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ge  related-EBV  association.  In  addition,  latency  III  pattern
ogether  with  lytic  viral  antigen  expression  in  DLBCL  from
rgentina  suggest  that  lytic  cycle  may  play  an  unexpected
ole  in  virus-mediated  oncogenesis.
In  order  to  reinforce  the  hypothesis  of  EBV-association
ot  exclusively  related  to  elderly  patients,  DLBCL  microen-
ironment  was  studied  in  pediatric,  younger  and  older  than
0  years  old  patients.  CD3,  CD8,  CD4  and  Foxp3  positive  cells
ere  compared  in  those  three  groups  and  in  relation  to  EBV
resence.  Remarkably,  we  did  not  observe  major  differences
inked  with  age  of  the  relative  numbers  of  any  T-cell  popula-
ion  analyzed.40,42 This  fact,  together  with  EBV  association
ith  both  age  groups,  might  confirm  previous  statements
hat  the  definitional  cutoff  of  50  years  proposed  by  the  WHO
ould  be  arbitrary48 because  cases  <  50  years  of  age  can  be
ound  and  suggest  that,  at  least  for  T-cell  populations  ana-
yzed,  immunosenescence  could  be  ruled  out.  Concerning
BV  status,  no  significant  difference  was  found  among  each
ellular  marker  investigated.40,42
. Concluding remarks and future
erspectives
rom  the  first  discovery  of  EBV  particles  in  sub-Saharan
urkitt’s  lymphoma,  the  virus  has  now  been  found  in  many
ore  tumors  of  B,  T,  NK  and  epithelial  cell  origin.  Over-
ll,  EBV  seems  to  contribute  to  ∼2%  of  all  tumor  burdens
n  man.  Therefore,  the  question  that  drives  most  research
nto  EBV  since  its  discovery  is  why  some  individuals  develop
BV-associated  tumors,  whereas  most  control  the  virus
ithout  symptoms.49 In  fact,  it  remains  to  be  elucidated
hether  EBV-association  with  lymphoma  reflects  causality.
he  increased  risk  of  HL  development  a  few  years  after
M  leads  to  speculate  that  a  similar  association  may  exist
etween  primary  EBV  infection  and  HL  risk  at  any  age,
or  example,  in  childhood.  A  higher  prevalence  of  EBV  in
ymphomas  diagnosed  in  children  <  10  years  old  was  demon-
trated  by  our  research  group  not  only  in  pediatric  HL,20,21
ut  also  in  BL34 and  DLBCL.42 Therefore,  in  our  country,  EBV
nfection  shows  interesting  epidemiological  characteristics
o  study  viral  pathogenesis.  Given  that  in  Argentina  children
re  infected  quite  early  in  their  life  and  nearly  70%  of  chil-
ren  are  seropositive  by  the  age  of  2  years,10 we  hypothe-
ize  that  infection  with  EBV  early  in  life  increases  the  risk
f  developing  EBV-associated  lymphoma  and  may  be  as  a
ate  complication  of  primary  infection.  A  comparison  of  EBV-
ositive  pediatric  lymphomas  between  developed  countries
nd  our  own  data  from  Argentina  is  presented  in  Table  1. It
s  well  accepted  that  HL  often  precedes  IM  and  that  IM  is  an
dolescent/young  adult  disease,  but  to  our  knowledge  there
s  not  a  clear  consensus  of  the  median  age  of  presentation
n  developed  countries.  Still  more  confusing  is  the  literature
bout  BL  and  DLBCL  because  most  studies  do  not  distinguish
etween  EBV-positive  and  -negative  cases  and  because  of
he  multiple  presentation  forms;  for  instance,  BL  sporadic,
ndemic  or  HIV  associated  and  DLBCL  of  immunocompetent
r  immunosuppressed  patients.Please  cite  this  article  in  press  as:  Chabay  P,  Preciado  MV.  Epi
phomas  from  Argentina.  Bol  Med  Hosp  Infant  Mex.  2015.  http:/
Our  preliminary  results  in  tonsils  from  pediatric  carri-
rs  show  that  a  latency  III  pattern  prevails  and,  based  on
he  known  oncogenic  potential  of  EBV  in  vitro, we  can  pro-
ose  that  the  synergism  of  oncogenic  viral  proteins  could
1
 PRESS
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ccur  in  these  cases  (personal  observations).  This  finding
uggests  that  there  could  be  an  implication  of  EBV  infection
nvolved  in  B-cell  lymphoma  development  in  our  country,
nd  emphasizes  the  need  for  epidemiological  studies  involv-
ng  different  centers  from  the  Latin  American  region  to
onfirm  this  hypothesis.
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